Wall Street Analysts Are Bullish on Top Healthcare Picks

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerulean Pharma (NASDAQ: CERU), Conatus Pharmaceuticals (NASDAQ: CNAT) and Aclaris Therapeutics Inc (NASDAQ: ACRS) with bullish sentiments.

Cerulean Pharma (NASDAQ: CERU)

In a report released today, John Newman from Canaccord Genuity reiterated a Buy rating on Cerulean Pharma (NASDAQ: CERU), with a price target of $6. The company’s shares closed yesterday at $0.70, close to its 52-week low of $0.63.

According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -16.9% and a 30.0% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.

Cerulean Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

Conatus Pharmaceuticals (NASDAQ: CNAT)

JMP Securities analyst Liisa Bayko reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT) today. The company’s shares closed yesterday at $1.56, close to its 52-week low of $1.40.

According to TipRanks.com, Bayko is a 1-star analyst with an average return of -1.4% and a 37.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Conatus Pharmaceuticals is Strong Buy and the average price target is $10.50, representing a 573.1% upside.

In a report issued on November 4, FBR Capital also reiterated a Buy rating on the stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS)

In a report released today, Donald Ellis from JMP Securities reiterated a Buy rating on Aclaris Therapeutics Inc (NASDAQ: ACRS). The company’s shares closed yesterday at $20.53.

According to TipRanks.com, Ellis is a 4-star analyst with an average return of 9.9% and a 45.5% success rate. Ellis covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Horizon Pharma Inc., and Endo International.

Aclaris Therapeutics Inc has an analyst consensus of Moderate Buy.